About us

The BWPG is comprised of physicians with expertise in precision medicine and human genetics. 

Our staff pedigree includes the country's top medical centers. Our members currently include 8 board-certified Molecular Genetic Pathologists and 4 Oncologists who practice precision medicine.

Our ancillary team also provides support for QA/QC, Bioinformatics, regulatory and compliance, and Marketing. 

Dr. Bien-Willner is the Executive Chairman of the Bien-Willner Physicians Association, a private molecular diagnostics and consulting services company.  He is dual-boarded in Anatomic Pathology and Molecular Genetic Pathology, and has expertise in genetics and genomics, as well as next-generation sequencing technology and pipeline design. 

Prior to leading the BWPG, Dr. Bien-Willner served as Medical and Laboratory Director for national and international reference laboratories. In addition to leadership roles in Industry, he served as a faculty member in the department of Pathology and Immunology at Washington University in St. Louis.  There, his research endeavors included cancer biomarker discovery and the development of novel genomic technologies. 

Dr. Bien-Willner completed his residency, fellowship, and post-doctoral training at Washington University.  His post-doctoral research was in the laboratory of Robi Mitra, Ph.D., who was one of the early developers of the technology that ultimately became today’s Illumina sequencing platform.  Dr. Bien-Willner earned his M.D. and Ph.D. degrees at Baylor College of Medicine in Houston, TX.  His Ph.D. in Human Molecular Genetics was in the laboratory of James R. Lupski, M.D.,Ph.D., a member of the National Academy of Sciences. 

Dr. Bien-Willner has received several prestigious awards for his research, including the Stowell-Orbison Award, the Association for Molecular Pathology Young Investigator Award, and has been designated a College of American Pathologist Scholar.  He has numerous peer-reviewed publications in journals including The American Journal of Human Genetics, Nature Communications, Neuro-Oncology, Human Molecular Genetics, Human Genetics, Clinical Genetics, and Acta Neuropathologica Communications, among others.

Dr. Berz is a triple board certified physician scientist with expertise in Internal Medicine, Hematology and Oncology.

He has extensive experience in precision medicine, cancer genomics,  biomarker discovery and drug development. He has functioned as principal investigator in multiple clinical phase I, II and III trials.

Born and raised in Germany, Dr. Berz earned his B.S. in Chemistry from Johann Wolfgang von Goethe Universitaet, Frankfurt and his M.D./Ph.D. from the Humboldt University, Berlin. He completed his internship and residency in Internal Medicine at Yale-affiliated Norwalk Hospital in Connecticut and his fellowship in Hematology and Oncology at Brown University. He is a member of the International Association for the Study of Lung Cancer, Melanoma Research Society, the American Society of Clinical Oncology and the American Society of Hematology. His areas of specialty include lung malignancies, melanoma, cancer immune therapy and personalized oncology therapeutics, and he serves as a frequent speaker and international thought leader in these areas. Dr. Berz has key oncology publications in major journals across the United States and Europe and continues to lead multiple research efforts and investigational trials. He continues to function as key opinion leader and consultant for multiple pharmaceutical industry partners. He has numerous peer-reviewed publications in journals including The American Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Journal of Experimental Hematology and Oncology, among others.

Grzegorz (Greg) Gurda, MD, PhD, is a dual-boarded in Molecular Genetic Pathology and Anatomic/Clinical Pathology.  He is the director of the Gundersen Cancer Biobank within the Kabara Cancer Research Institute.

Dr. Gurda Completed his Undergraduate studies at the University of Chicago, and his MD/PhD training at the University of Michigan, with a PhD in Molecular and Integrative Physiology.  His residency training was completed at The Johns Hopkins Hospital, and his fellowship at the University of Pittsburgh Medical Center (UPMC). 

Dr. Gurda has won several notable awards including a Howard Hughes and Max Kade Foundation Fellowship, as well as the Young Investigator Award from the Americal Pancreatic Association.

Jason N. Rosenbaum is an Assistant Professor at the University of Pennsylvania, Perelman School of Medicine in the Department of Pathology and Laboratory Medicine, and the Associate Director of the Molecular Genetic Pathology (MGP) Fellowship Program. Jason completed his MGP fellowship at the Washington University School of Medicine in St. Louis, and his residency at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin. Jason is also certified in anatomic and clinical pathology by the American Board of Pathology.

Jason maintains an active research program, with projects investigating the detection and interpretation of chromosomal rearrangements and oncogenic transcripts by next-generation sequencing (NGS). Jason also has worked to develop novel immunohistochemical and molecular markers for neuroendocrine carcinoma. 

Jason has demonstrated leadership in a number of arenas during his training, including service on the Association for Molecular Pathology Training & Education and Professional Relations Committees, the College of American Pathologists Committee for Biomarker Reporting and Pennsylvania delegation

Jason attended the Northwestern University Feinberg School of Medicine, earning his MD in 2011. There he did research into the embryonic development and evolution of the nervous system.